| Literature DB >> 31681410 |
Marie R Mooney1, Erica E Davis1,2,3, Nicholas Katsanis1,2,3.
Abstract
Therapeutic applications of CRISPR-Cas9 gene editing have spurred innovation in Cas9 enzyme engineering and single guide RNA (sgRNA) design algorithms to minimize potential off-target events. While recent work in rodents outlines favorable conditions for specific editing and uses a trio design (mother, father, offspring) to control for the contribution of natural genome variation, the potential for CRISPR-Cas9 to induce de novo mutations in vivo remains a topic of interest. In zebrafish, we performed whole exome sequencing (WES) on two generations of offspring derived from the same founding pair: 54 exomes from control and CRISPR-Cas9 edited embryos in the first generation (F0), and 16 exomes from the progeny of inbred F0 pairs in the second generation (F1). We did not observe an increase in the number of transmissible variants in edited individuals in F1, nor in F0 edited mosaic individuals, arguing that in vivo editing does not precipitate an inflation of deleterious point mutations.Entities:
Keywords: CRISPR-Cas9; de novo mutation; exome; off-target effect; zebrafish
Year: 2019 PMID: 31681410 PMCID: PMC6797590 DOI: 10.3389/fgene.2019.00949
Source DB: PubMed Journal: Front Genet ISSN: 1664-8021 Impact factor: 4.599
Figure 1Whole exome sequencing in two generations of CRISPR-Cas9 edited zebrafish. (A) The experimental design generates a single clutch of ∼200 embryos from a founder pair of parents from the ZDR laboratory strain of wild-type zebrafish. The embryos were randomly assigned to four experimental arms: uninjected controls, Cas9 injected controls, sgRNA injected controls, and Cas9 + sgRNA gene edited samples. A total of 52 embryos were sampled for DNA extraction and sequencing at 4 dpf in the F0 generation (2 uninjected, 2 Cas9 injected, 2 sgRNA injected across 6 different sgRNAs targeting 3 genes for a total of 12 embryos, and 6 CRISPR-Cas9 embryos per sgRNA guide for a total of 36 edited individuals). Additional embryos for each condition were injected concurrently, but raised to adulthood. The F0 in-cross from pairs edited with the smchd1 high efficiency guide generated F1 progeny for further sequencing: We sampled offspring from 4 uninjected, 4 Cas9 injected, 4 sgRNA injected, and 4 CRISPR-Cas9 injected embryos for a total of 16 F1 exomes. (B) The first round of exome sequencing (F0 and parents) generated a consistent read depth averaging 76x coverage. (C) The second round of exome sequencing (F1) generated a consistently higher read depth averaging 115x coverage. The smchd1 edited individuals are also sequenced to a higher depth than the uninjected controls (p < 0.05). (D) After sequencing quality control and alignment, variant calling was performed with both somatic and germline callers to identify candidate de novo mutations.
Figure 2Counts of candidate de novo mutations in control and edited individual zebrafish embryos. Variants persisting after filtering and with an allele frequency ≥0.3 are not significantly different between control and CRISPR-Cas9 edited groups (N = 68). (A) Predicted counts by VarScan2. (B) Unambiguous heterozygous variants determined by visual inspection of VarScan2 calls in IGV (C) Subset of predicted variants detected by both variant callers.